High expression of TOP2A in many types of tumors, such as non-small cell lung cancer, hepatocellular carcinoma, and breast cancer, has been proven to be a dependable proliferation marker and is associated with disease progression and poor prognosis (8–10). This evidence concerns the gene TOP2A and breast cancer.